Literature DB >> 12751780

Results of conservative management of epithelial malignant and borderline ovarian tumours.

Philippe Morice1, Sophie Camatte, Fabienne Wicart-Poque, David Atallah, Roman Rouzier, Patricia Pautier, Christophe Pomel, Catherine Lhommé, Pierre Duvillard, Damienne Castaigne.   

Abstract

Conservative management of at least part of both the ovary and uterus can be proposed in patients with borderline ovarian tumour, in order to preserve fertility potential. This conservative management could be carried out even in patients with borderline ovarian tumour associated with non-invasive peritoneal implants (if complete resection of peritoneal disease has been performed). When facing persistent infertility after this conservative surgery, ovarian induction or an in-vitro procedure could be proposed in patients with an early-stage disease, though the number of attempts must be limited. Removal of the preserved ovary after completion of pregnancy(ies) is unnecessary if patients agree to careful follow-up. In patients with epithelial ovarian cancer, conservative management could safely be performed in young patients who wish to preserve fertility function and who fulfil the following criteria: unilateral tumour (stage IA), grade 1 (and 2?), adequate staging surgery and careful follow-up. Removal of the preserved ovary should be carried out after completion of pregnancy(ies) in order to reduce the risk of ovarian tumour recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12751780     DOI: 10.1093/humupd/dmg006

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  8 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

2.  Laparoscopic restaging of borderline ovarian tumors.

Authors:  E Daraï; L Tulpin; H Prugnolle; A Cortez; G Dubernard
Journal:  Surg Endosc       Date:  2007-05-19       Impact factor: 4.584

3.  Oncologic and obstetric outcomes of conservative surgery for borderline ovarian tumors in women of reproductive age.

Authors:  Se Yun Lee; Min Chul Choi; Bo Ram Kwon; Sang Geun Jung; Hyun Park; Won Duk Joo; Chan Lee; Je Ho Lee; Joon Mo Lee
Journal:  Obstet Gynecol Sci       Date:  2017-05-15

4.  A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.

Authors:  Pia Leandersson; Anna Åkesson; Ingrid Hedenfalk; Susanne Malander; Christer Borgfeldt
Journal:  PLoS One       Date:  2020-10-19       Impact factor: 3.240

5.  Retrospective Analysis of Factors Affecting Recurrence in Borderline Ovarian Tumors.

Authors:  Mariam Anjum Ifthikar; Anupama Rajanbabu; Indu R Nair; Vinita Murali; Anjaly S Nair
Journal:  South Asian J Cancer       Date:  2021-03-19

Review 6.  Fertility preservation during cancer treatment: clinical guidelines.

Authors:  Kenny A Rodriguez-Wallberg; Kutluk Oktay
Journal:  Cancer Manag Res       Date:  2014-03-04       Impact factor: 3.989

7.  Tumors of low malignant potential a single institution experience.

Authors:  Ichraf Jbir; Montassar Ghalleb; Amira Triki; Ines Zemni; Monia Hechiche; Jamel Ben Hassouna; Khaled Rahal
Journal:  Int J Surg Case Rep       Date:  2019-01-19

8.  Analysis of Factors Influencing Relapse and Pregnancy in Patients with Borderline Ovarian Tumors.

Authors:  Ya Qi; Min Wang; Yuwei Yang; Zhi Zeng; Yingying Zhou
Journal:  J Cancer       Date:  2021-07-02       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.